QUEBEC CITY, Aug. 13, 2015
Continuing with his commentary on the second quarter, Mr. Dodd stated, "During the first quarter of this year, we made the decision to raise a significant amount of capital to see us through the next 18 months of the implementation of our strategy. As a result, we are in a strong financial position with cash and cash equivalents of approximately $45.5 million as of June 30. However, the pressure being exerted on our stock price since our public offering does not reflect this strong cash position, our recent achievements and overall corporate value. We believe that the dilution attributable to warrants issued in the offering during the first quarter is the reason for the pressure on our stock price and that such dilution could continue for the next several months. Nonetheless, we remain focused on our upcoming drug development and commercial milestones which we believe will enable us to ultimately achieve our goal of becoming a commercially operating specialty biopharmaceutical company."
http://www.ariva.de/news/...r-Financial-and-Operating-Results-5458150
August 2015 + 18 Monate = Jan 17
Was hat Dodd gesagt?
Commenting on the filing, David A. Dodd, Chairman, President and Chief Executive Officer of the Company stated, “The Shelf Prospectus is intended to give us the ability to access new capital in the future. Taking into account our current operations and capital requirements, the offering we completed earlier this month is expected to provide sufficient capital to see us through the first quarter of 2017.
http://www.ariva.de/news/...Preliminary-Base-Shelf-Prospectus-5601590
Wirklich noch eine KE?????????
Schauen wir mal.
|
